Head-To-Head Comparison: OncoMed Pharmaceuticals (OMED) & Its Rivals
OncoMed Pharmaceuticals (NASDAQ: OMED) is one of 182 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare OncoMed Pharmaceuticals to related businesses based on the strength of its profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Insider and Institutional Ownership
50.4% of OncoMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 32.8% of OncoMed Pharmaceuticals shares are owned by insiders. Comparatively, 14.6% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of current recommendations for OncoMed Pharmaceuticals and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|OncoMed Pharmaceuticals Competitors||504||2384||6468||121||2.65|
OncoMed Pharmaceuticals currently has a consensus target price of $6.00, suggesting a potential upside of 17.65%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.69%. Given OncoMed Pharmaceuticals’ higher possible upside, analysts plainly believe OncoMed Pharmaceuticals is more favorable than its rivals.
Valuation & Earnings
This table compares OncoMed Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|OncoMed Pharmaceuticals||$25.15 million||-$103.10 million||-2.70|
|OncoMed Pharmaceuticals Competitors||$215.30 million||-$39.30 million||-67.32|
OncoMed Pharmaceuticals’ rivals have higher revenue and earnings than OncoMed Pharmaceuticals. OncoMed Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
OncoMed Pharmaceuticals has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500. Comparatively, OncoMed Pharmaceuticals’ rivals have a beta of 1.53, meaning that their average share price is 53% more volatile than the S&P 500.
This table compares OncoMed Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|OncoMed Pharmaceuticals Competitors||-3,206.45%||-546.13%||-38.02%|
OncoMed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
Receive News & Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.